In keeping with these findings, Chi et al. also reported reductions in CD4+ CD25+ T cells in the initial stages of GBS and an increase in their numbers following IVIg therapy (Chi et al., 2007). This evidence concerns the gene CD4 and Guillain-Barre syndrome.